Cyber Incident Victim: YposKesi
Date:
Mar 2021
Location:
France
Summary
A biotechnology firm specializing in gene and cell therapy production was compromised by the Babuk ransomware group, which exfiltrated approximately 23 GB of data from its systems. The attackers publicly claimed responsibility for the intrusion on their DarkWeb platform, highlighting the healthcare sector as a recurring target for this emerging ransomware variant. The incident impacted a company recognized for its advanced therapeutic research and industrial capabilities, underscoring vulnerabilities in critical medical infrastructure.
| CIA Posture | Motives | Tactics, Techniques & Procedures |
|---|---|---|
| Available to members | 1 motive | 1 technique |
| Threat Actor | Type | Location |
|---|---|---|
| 1 actor | Available to members | Available to members |
Description
On March 27, 2021, the Babuk ransomware group publicly claimed responsibility for a cyberattack against YposKesi, a French biotechnology company specializing in advanced gene and cell therapy production. The attackers announced the compromise on their Dark Web platform, disclosing the theft of approximately 23 GB of data from YposKesi's systems. The intrusion reportedly occurred on the evening of March 26, 2021, though specific technical details regarding initial access vectors or malware deployment methods were not disclosed in available reporting. YposKesi, developed through the research efforts of the Généthon laboratory, represented a significant pharmaceutical manufacturing entity with expertise in cutting-edge therapeutic production. The company's prominence in the biotechnology sector likely contributed to its targeting by the threat actors.
Babuk operators explicitly identified healthcare organizations as their preferred targets, aligning with broader trends of ransomware groups increasingly focusing on medically related entities during this period. The publication of stolen data on their Dark Web leak site followed standard ransomware group procedures to pressure victims into paying extortion demands, though YposKesi's response to the attack and any potential ransom negotiations remain undocumented in public sources. Security researchers monitoring Dark Web activity first identified the breach claim through Babuk's communications channel. The incident highlighted vulnerabilities within critical biotechnology infrastructure supporting medical research and therapeutic development. No further technical specifics regarding containment measures, forensic investigations, or operational impacts on YposKesi's research and manufacturing capabilities were detailed in the source material.